Some studies have recently suggested the partial loss of SMARCB1/INI1 expression at immunohistochemistry as a poor prognostic marker of outcome, being associated with higher recurrence rates and shorter survival in patients with other tumor types, including colorectal, pancreatic, uterine and sinonasal carcinomas (12–16). The gene discussed is SMARCB1; the disease is nasal cavity and paranasal sinus carcinoma.